Overview: This presentation (this "Presentation") dated November 17, 2025, has been prepared by Southern Cross Gold Consolidated Ltd ("SXGC" or the "Company") and is authorized for release by Managing Director, Michael Hudson. Sunday Creek An Expanding and Significant Global Gold Discovery Michael Hudson Managing Director AGM - 17 November 2025 For personal use only Accuracy of Information: Readers are directed to the public disclosure of Southern Cross Gold Consolidated Ltd ("SXGC") available under SXGC's ...

AI-Powered Marketing Technology Solutions Q3 2025 Financial Results Conference Call November 14, 2025 NASDAQ: BNZI Disclaimers Basis of Presentation This Presentation (this "Presentation") is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential investment in Banzai International, Inc. ("Banzai" or the "Company") and for no other purpose. By accepting, reviewing or reading this Presentation, you will be deemed t ...

Q3 2025 Financial Results Revenue and Adjusted EBITDA | | | | ($000's) Three Months Ended September 30, | | | | | ($000's) Nine Months Ended September 30, | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | Period-over- | | | | | Period-over | | | 2025 | | 2024 | | Period % | | 2025 | 2024 | | Period % | | | Unaudited | | Unaudited | | Change | | Unaudited | Unaudited | | Change | | Revenue | $ | 7,762 | $ | 4,686 | 66% | $ | 22,294 | $ | 14,341 | 55% | | Net loss | $ | (15 ...

Financial Performance - Cemig's Recurring EBITDA decreased by 16.3% from R$1,762 million in 3Q24 to R$1,475 million in 3Q25 [37] - Recurring Net Profit decreased by 30.2% from R$1,118 million in 3Q24 to R$780 million in 3Q25 [37] - Cemig D's Recurring EBITDA decreased by 4.7% from R$773 million in 3Q24 to R$737 million in 3Q25 [66] - Cemig D's Recurring Net Profit decreased by 28.0% from R$372 million in 3Q24 to R$268 million in 3Q25 [66] - Cemig GT's EBITDA decreased by 12.6% from R$602 million in 3Q24 to R$526 million in 3Q25 [90] - Cemig GT's Net Profit decreased by 17.6% from R$467 million in 3Q24 to R$385 million in 3Q25 [90] - Gasmig's EBITDA decreased by 16.0% [97] Investments - Investments grew by 17.0% in 9M25/9M24, totaling R$4,7 billion [14, 16] - Distribution investments reached R$3,602 million [19] - Generation investments reached R$149 million [19] - Transmission investments reached R$297 million [19] - Gasmig's Central-Oeste project has an estimated CAPEX of R$800 million, with R$675 million realized until September 2025 (84%) [97] Operational Highlights - Additional Allowed Annual Revenue (RAP) of R$32.3 million in 9M25, 12.5% above the additional RAP in 12M24, equivalent to a total of R$28.7 million [31] - Cemig D's market, including Micro and Mini Distributed Generation (DG), declined by 2.0% [72]

NYSE-A:CTGO CORPORATE PRESENTATION Investors are cautioned that while the S-K 1300 definitions are "substantially similar" to the NI 43-101 definitions, there are differences between the two. Accordingly, there is no assurance any mineral reserve or mineral resource estimates that Peak Gold may report as "probable mineral reserves", "measured mineral resources", "indicated mineral resources" and "inferred mineral resources" under NI 43-101 would be the same had CORE prepared the mineral reserve or mineral r ...

Year-end fiscal 2025 update November 14, 2025 Forward-looking statements and use of non-GAAP measures This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Our forward-looking statements in this presentation speak only as of today, and we assume no duty to update them. Forward- looking statements are typically identified by words such as, but not limited to: "estimates," "expects," "anticipates," "intends," "targets," "plans," "fore ...

Quarter 3 2025 Financial Results Disclaimer Cautionary Language Regarding Forward-Looking Statements This slide deck contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Act"), and are intended to enjoy the protection of the safe harbor for forward-looking statements provided by the Act as well as protections afforded by other federal securities laws. Such forward-looking statements include but are not limited to: the expected timing ...

Financial Performance Highlights - Credicorp achieved a Return on Equity (ROE) of 19.6%[14] - Risk-Adjusted Net Interest Margin (NIM) increased by 9 basis points compared to 2Q25, reaching 5.5%[14] - The efficiency ratio for 3Q25 was 46.4%[14] - BCP's CET1 ratio stood at 13.17% in September 2025[14] - The coverage ratio was 110.1%[14] Loan Portfolio and Asset Quality - Total loans increased by 1.5% year-over-year[17] - FX Neutral Loan Growth was 7.0% year-over-year[17] - The NPL (Non-Performing Loan) ratio decreased by 105 basis points year-over-year to 4.8%[17] - The Cost of Risk (CoR) decreased by 71 basis points year-over-year to 1.7%[17] Income and Funding - Net Interest Income (NII) increased by 2.7% year-over-year[17] - Low-cost deposits constituted 58.1% of the funding base, an increase of 185 basis points year-over-year[17] - Fee income increased by 8.2% year-over-year[17] - Gains on FX transactions increased by 23.4% year-over-year[17] - Insurance underwriting results increased by 33.1% year-over-year[17] Yape Digital Platform - Yape's lending revenue share increased from 7% in 3Q24 to 20% in 3Q25[44] - Yape disbursed loans to 3.4 million clients in 3Q25[44]

Company Overview - ImmuCell focuses on growth in sales of the First Defense product line and enhancing subclinical mastitis treatment with Re-Tain[10] - The company addresses the $2 billion annual economic harm to the dairy industry due to mastitis infections with Re-Tain, aiming to reduce antibiotics in the food chain[10] - The company completed an investment to increase First Defense production capacity to over $30 million in annual sales value[29, 51] Product Lines and Market Opportunity - The U S market opportunity for calf-level products to prevent scours is about $311 million annually[31, 55] - The U S market opportunity for calf-level and dam-level vaccine products used to prevent scours is estimated at about $818 million[31, 55] - Mastitis causes approximately $2 billion in economic loss to the dairy industry each year[10, 32, 56, 57] Financial Performance - As of September 30, 2025, the company had $39 million in cash and cash equivalents[88] - As of October 31, 2025, the company's market capitalization was $564 million, with a stock price of $624 per share and 905 million shares outstanding[88] - Product sales for the nine-month period ended September 30, 2025, were $20 million, compared to $187 million for the same period in 2024[91] - Gross margin for the three-month period ended September 30, 2025, was 43%, compared to 26% for the same period in 2024[91]

Third Quarter 2025 Results Presentation Cautionary statement This presentation contains non -IFRS and other financial measures and forward -looking statements, including a discussion of our business targets, expectations, and outlook. We caution readers not to place undue reliance on our forward - looking statements since a number of factors could cause actual future results to differ materially from the targets and expectations expressed. Non -IFRS and other financial measures do not have a standardized me ...